{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-23-000015","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.867280+00:00","generated_at":"2026-06-18T01:16:35.937371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apyx Medical Q4 2022 revenue down 25% to $12.6M; net loss $6.0M; guides 2023 rev $58-61M","bullets":["Q4 total revenue $12.6M (-25% YoY); Advanced Energy segment $10.5M (-30% YoY); OEM $2.1M (+15% YoY).","FY2022 net loss $23.2M ($0.67/share) vs $15.2M in 2021; adjusted EBITDA loss $15.4M vs $8.8M.","Introduces FY2023 guidance: total revenue $58-61M (30-37% growth); net loss ~$14M vs $23.2M in 2022.","Post-quarter: FDA 510(k) clearance for Renuvion APR Handpiece (Feb 27); $35M credit facility with MidCap Financial.","CEO cites FDA Safety Communication disruption; expects >35% Advanced Energy growth in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-23-000015","json":"https://secwatch.observer/filing/0000719135-23-000015.json","markdown":"https://secwatch.observer/filing/0000719135-23-000015.md","text":"https://secwatch.observer/filing/0000719135-23-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/0000719135-23-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/apyx-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:16:35.937371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14463ee315af949998a896a661c145d82af1b98c","claim":"Apyx Medical Corp reported full year ended December 31, 2022 results: revenue $44.5 million, net income Net loss attributable to stockholders of $23.2 million. Guidance initiated.","evidence_excerpt":"the fourth quarter of 2021. • Adjusted EBITDA loss of $4.1 million, compared to $0.3 million for the fourth quarter of 2021. Full Year 2022 Financial Summary: • Total revenue of $44.5 million, down 8% year-over-year. ◦ Advanced Energy revenue of $36.8 million, down 14% year-over-year. ◦ OEM revenue of $7.7 million, up 39% year-over-year. • Net loss attributable to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/0000719135-23-000015-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Revenue","value":"$44.5 million"},{"label":"Net income","value":"Net loss attributable to stockholders of $23.2 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"92ee111731ec28d3e49d8e51c616e81bbd668ba4","claim":"Apyx Medical Corp reported for the fourth quarter and year ended December 31, 2022 results: revenue $12.6 million, net income Net loss attributable to stockholders of $6.0 million.","evidence_excerpt":"full year ended December 31, 2022, and introduced financial expectations for the full year ending December 31, 2023. Fourth Quarter 2022 Financial Summary : • Total revenue of $12.6 million, down 25% year-over-year. ◦ Advanced Energy revenue of $10.5 million, down 30% year-over-year. ◦ OEM revenue of $2.1 million, up 15% year-over-year. • Net loss attributable to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/0000719135-23-000015-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$12.6 million"},{"label":"Net income","value":"Net loss attributable to stockholders of $6.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}